Pivotal role of animal models in the development of new therapies for cytomegalovirus infections

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 164-171

  Kern, Earl R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Animal models; Cytomegalovirus; Guinea pig; Mouse; Rat

Indexed keywords

ALDEHYDE DERIVATIVE; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; CYCLOPROPANE DERIVATIVE; CYCLOPROPAVIR; ESTER DERIVATIVE; FOSCARNET; GANCICLOVIR; HEXADECYLOXYPROPYLCYCLOPROPAVIR; OCTADECYLOXYETHYLCYCLOPROPAVIR; RIBONUCLEOSIDE DERIVATIVE; TOMEGLOVIR; UNCLASSIFIED DRUG;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SCREENING; GUINEA PIG; HUMAN; IMMUNE DEFICIENCY; LABYRINTHITIS; MEDICAL INFORMATION; NEPHROTOXICITY; NONHUMAN; PERCEPTION DEAFNESS; PREDICTION; PRIORITY JOURNAL; SCID MOUSE; SHORT SURVEY;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; MICE; MICE, SCID; RATS;

ANIMALIA; CAVIA PORCELLUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MURINAE;

EID: 33747343175     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.018     Document Type: Short Survey

References (94)

1. Alford C.A. Chronic intrauterine and perinatal infections. In: Galasso G.J., Merigan T.C., and Buchanan R.A. (Eds). Antiviral Agents and Viral Diseases of Man (1984), Raven Press, New York 443-486
2. Allen L.B., Li S.X., Arnett G., Toyer B., Shannon W.M., and Hollingshead M.G. Novel method for evaluating antiviral drugs against human cytomegalovirus in mice. Antimicrob. Agents Chemother. 36 (1992) 206-208
3. Balfour Jr. H.H., Chace B.A., Stapleton J.T., Simmons R.L., and Fryd D.S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320 (1989) 1381-1387
4. Barry P.A., Lockridge K.M., Salamat S., Tinling S.P., Yue Y., Zhou S.S., Gospe Jr. S.M., Britt W.J., and Tarantal A.F. Non human primate models of intrauterine cytomegalovirus infection. ILAR J. 47 (2006) 49-64
5. Bernstein D.I., and Bourne N. Animal models for cytomegalovirus infections: guinea-pig CMV. In: Zak O., and Sande M.A. (Eds). Handbook of Animal Models of Infection (1999), Academic Press, San Diego 935-941
6. Bia F.J., Griffith B.P., Fong C.K., and Hsiung G.D. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev. Infect. Dis. 5 (1983) 177-195
7. Bidanset D.J., Beadle J.R., Wan W.B., Hostetler K.Y., and Kern E.R. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J. Infect. Dis. 190 (2004) 499-503
8. Bidanset D.J., del Cerro M., Lazar E.S., Faye-Petersen O., and Kern E.R. Animal model for ocular human cytomegalovirus infections in SCID-hu mice. In: Zak O., and Sande M.A. (Eds). Handbook of Animal Models of Infection (1999), Academic Press, London, United Kingdom 957-962
9. Bidanset D.J., Rybak R.J., Hartline C.B., and Kern E.R. Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue. J. Infect. Dis. 184 (2001) 192-195
10. Boivin G., Gilbert C., Gaudreau A., Greenfield I., Sudlow R., and Roberts N.A. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184 (2001) 1598-1602
11. Boppana S.B., Fowler K.B., Pass R.F., Rivera L.B., Bradford R.D., Lakeman F.D., and Britt W.J. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J. Pediatr. 146 (2005) 817-823
12. Bourne N., Bravo F.J., and Bernstein D.I. Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Antiviral Res. 47 (2000) 103-109
13. Bowen E.F., Emery V.C., Wilson P., Johnson M.A., Davey C.C., Sabin C.A., Farmer D., and Griffiths P.D. Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. AIDS 12 (1998) 605-611
14. Bratcher D.F., Bourne N., Bravo F.J., Schleiss M.R., Slaoui M., Meyers M.G., and Bernstein D.I. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J. Infect. Dis. 172 (1995) 944-950
15. Bravo F.J., Bourne N., Schleiss M.R., and Bernstein D.I. An animal model of neonatal cytomegalovirus infection. Antiviral Res. 60 (2003) 41-49
16. Bravo F.J., Cardin R.D., and Bernstein D.I. Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 193 (2006) 591-597
17. Bravo F.J., Stanberry L.R., Kier A.B., Vogt P.E., and Kern E.R. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Res. 21 (1993) 59-72
18. Britt W.J. Primate models: Pros and Cons. In: Reddehase M.J. (Ed). Cytomegalovirus, Molecular Biology and Immunology (2006), Academic Press, Wymondham, UK 591-605
19. Brown J.M., Kaneshima H., and Mocarski E.S. Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. J. Infect. Dis. 171 (1995) 1599-1603
20. Bruggeman C.A., Engels W., and Endert J. Treatment of experimental cytomegalovirus infections with acyclovir. Arch. Virol. 97 (1987) 27-35
21. Choi Y.C., and Hsiung G.D. Cytomegalovirus infection in guinea pigs. II. Transplacental and horizontal transmission. J. Infect. Dis. 138 (1978) 197-202
22. Chou S., Lurain N.S., Thompson K.D., Miner R.C., and Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188 (2003) 32-39
23. Crippa F., Corey L., Chuang E.L., Sale G., and Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin. Infect. Dis. 32 (2001) 214-219
24. de Jong M.D., Galasso G.J., Gazzard B., Griffiths P.D., Jabs D.A., Kern E.R., and Spector S.A. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res. 39 (1998) 141-162
25. DiLoreto Jr. D., Epstein L.G., Lazar E.S., Britt W.J., and del Cerro M. Cytomegalovirus infection of human retinal tissue: an in vivo model. Lab. Invest. 71 (1994) 141-148
26. Duan J., Paris W., Kibler P., Bousquet C., Liuzzi M., and Cordingley M.G. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 39 (1998) 189-197
27. Enright H., Haake R., Weisdorf D., Ramsay N., McGlave P., Kersey J., Thomas W., McKenzie D., and Miller W. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 55 (1993) 1339-1346
28. Epstein L.G., Cvetkovich T.A., Lazar E., Dehlinger K., Dzenko K., del Cerro C., and del Cerro M. Successful xenografts of second trimester human fetal brain and retinal tissue in the anterior chamber of the eye of adult immunosuppressed rats. J. Neural Transplant Plast. 3 (1992) 151-158
29. Erice A., Borrell N., Li W., Miller W.J., and Balfour Jr. H.H. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178 (1998) 531-534
30. Fong C.K., Cohen S.D., McCormick S., and Hsiung G.D. Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Res. 7 (1987) 11-23
31. Fowler K.B., and Boppana S.B. Congenital cytomegalovirus (CMV) infection and hearing deficit. J. Clin. Virol. 35 (2006) 226-231
32. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., and Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118 (1993) 173-178
33. Griffith B.P., Chen M., and Isom H.C. Role of primary and secondary maternal viremia in transplacental guinea pig cytomegalovirus transfer. J. Virol. 64 (1990) 1991-1997
34. Griffith B.P., Lucia H.L., Bia F.J., and Hsiung G.D. Cytomegalovirus-induced mononucleosis in guinea pigs. Infect. Immun. 32 (1981) 857-863
35. Griffith B.P., Lucia H.L., Bia F.J., and Hsiung G.D. Brain and visceral involvement during congenital cytomegalovirus infection of guinea pigs. Pediatr. Res. 16 (1982) 455-459
36. Harrison C.J., and Myers M.G. Relation of maternal CMV viremia and antibody response to the rate of congenital infection and intrauterine growth retardation. J. Med. Virol. 31 (1990) 222-228
37. Jabs D.A., Enger C., Dunn J.P., and Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J. Infect. Dis. 177 (1998) 770-773
38. Jabs D.A., Martin B.K., Forman M.S., and Ricks M.O. Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression and occurrence of resistant CMV in patients with CMV retinitis. J. Infect. Dis. 192 (2005) 640-649
39. Kaptein S.J.F., Vink C., Bruggeman C.A., and Stassen F.R.M. The rat model for CMV infection and vascular disease. In: Reddechase M.J. (Ed). Cytomegaloviruses: Pathogenesis, Molecular Biology, and Immunology (2006), Horizon Scientific Press Ltd., Wymond, UK 501-523
40. Kemble G.W., Duke G.M., and Mocarski E.S. Human cytomegalovirus infection of the SCID-hu (Thy/Liv) mouse. In: Zak O., and Sande M.A. (Eds). Handbook of Animal Models of Infection (1999), Academic Press, London, United Kingdom 951-956
41. Kern E.R. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant Proc. 23 (1991) 152-155
42. Kern E.R. Preclinical evaluation of antiviral agents. In: Galasso G.J., Whitley R.J., and Merigan T.C. (Eds). Antiviral Agents and Human Viral Diseases. fourth ed. (1997), Raven Press, New York, NY 79-111
43. Kern E.R. Animal model for CMV infections: murine CMV. In: Zak O., and Sande M.A. (Eds). Handbook of Animal Models of Infection (1999), Academic Press, London, United Kingdom 927-934
44. Kern E.R., Bidanset D.J., Hartline C.B., Yan Z., Zemlicka J., and Quenelle D.C. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48 (2004) 4745-4753
45. Kern E.R., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., and Quenelle D.C. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48 (2004) 3516-3522
46. Kern E.R., Hartline C.B., Rybak R.J., Drach J.C., Townsend L.B., Biron K.K., and Bidanset D.J. Activities of benzimidazole d- and l-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother. 48 (2004) 1749-1755
47. Kern E.R., Rybak R.J., Hartline C.B., and Bidanset D.J. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Antiviral Chem. Chemother. 12 Suppl. 1 (2001) 149-156
48. Kimberlin D.W., Lin C.-Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., Jacobs R.F., Vaudry W., Pass R.F., Kiell J.M., Soong S.-J., and Whitley R.J. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus desease involving the central nervous system: a randomized controlled trial. J. Pediatr. 143 (2003) 16-25
49. Kushner N.L., Williams S.L., Hartline C.B., Harden E.H., Bidanset D.J., Chen X., Zemlicka J., and Kern E.R. Efficacy of methylenecyclopropane analogs of nucleosides against herpesvirus replication in vitro. Nucleosides Nucleotides Nucleic Acids 22 (2003) 2105-2119
50. Lalezari J.P., and Kuppermann B.D. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14 Suppl. 1 (1997) S27-S31
51. Laycock K.A., Fenoglio E.D., Hook K.K., and Pepose J.S. An in vivo model of human cytomegalovirus retinal infection. Am. J. Ophthalmol. 124 (1997) 181-189
52. Li S.B., Yang Z.H., Feng J.S., Fong C.K.Y., Lucia H.L., and Hsiung G.D. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 13 (1990) 237-252
53. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
54. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., and Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185 (2002) 20-27
55. Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J. Infect. Dis. 186 Suppl. 1 (2002) S99-S109
56. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., Norman D., Mendez R., Keating M.R., Coggon G.L., Crisp A., and Lee I.C. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340 (1999) 1462-1470
57. Lucia H.L., Griffith B.P., and Hsiung G.D. Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs. Intervirology 21 (1984) 141-149
58. Meyers J.D., Flournoy N., and Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153 (1986) 478-488
59. Mocarski E.S., Bonyhadi M., Salimi S., McCune J.M., and Kaneshima H. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 104-108
60. Nelson C.T., and Demmler G.J. Cytomegalovirus infection in the pregnant mother, fetus, and newborn infant. Clin. Perinatol. 24 (1997) 151-160
61. Neyts J., Balzarini J., Naesens L., and De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J. Med. Virol. 37 (1992) 67-71
62. Nigro G., Adler S.P., La Toree R., Best A.M., and Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 353 (2005) 1350-1362
63. O'Sullivan C.E., Drew W.L., McMullen D.J., Miner R., Lee J.Y., Kaslow R.A., Lazar J.G., and Saag M.S. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J. Infect. Dis. 180 (1999) 847-849
64. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998) 853-860
65. Pari G.S., Netski D., St Jeor S., McCarthy D., Smith J., Georgio D., and von Hofe E. Generation of a nude mouse tumor model for in vivo replication of human cytomegalovirus. J. Infect. Dis. 177 (1998) 523-528
66. Paya C.V., Wilson J.A., Espy M.J., Sia I.G., DeBernardi M.J., Smith T.F., Patel R., Jenkins G., Harmsen W.S., Vanness D.J., and Wiesner R.H. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J. Infect. Dis. 185 (2002) 854-860
67. Polis M.A., Spooner K.M., Baird B.F., Manischewitz J.F., Jaffe H.S., Fisher P.E., Falloon J., Davey Jr. R.T., Kovacs J.A., Walker R.E., Whitcup S.M., Nussenblatt R.B., Lane H.C., and Masur H. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39 (1995) 882-886
68. Razonable R.R., and Paya C.V. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infection. Herpes 10 (2003) 60-65
69. Reed J.B., Schwab I.R., Gordon J., and Morse L.S. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am. J. Ophthalmol. 124 (1997) 199-205
70. Reynolds D.W., Stagno S., Stubbs K.G., Dahle A.J., Livingston M.M., Saxon S.S., and Alford C.A. Inapparent congenital cytomegalovirus infection with elevated cord IgM levels. Casual relation with auditory and mental deficiency. N. Engl. J. Med. 290 (1974) 291-296
71. Ringden O., Lonnqvist B., Paulin T., Ahlmen J., Klintmalm G., Wahren B., and Lernestedt J.O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J. Antimicrob. Chemother. 17 (1986) 373-387
72. Rybak R.J., Hartline C.B., Qiu Y.L., Zemlicka J., Harden E., Marshall G., Sommadossi J.P., and Kern E.R. In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob. Agents Chemother. 44 (2000) 1506-1511
73. Rybak R.J., Zemlicka J., Qiu Y.L., Hartline C.B., and Kern E.R. Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides. Antiviral Res. 43 (1999) 175-188
74. Safrin S., Cherrington J., and Jaffe H.S. Clinical uses of cidofovir. Rev. Med. Virol. 7 (1997) 145-156
75. Schleiss M.R., Bernstein D.I., McVoy M.A., Stroup G., Bravo F., Creasy B., McGregor A., Henninger K., and Hallenberger S. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 65 (2005) 35-43
76. Schleiss M.R., Anderson J.L., and McGregor A. Cyclic cidofovir (HPMPC) prevents congenital cytomegalovirus infection in a guinea pig model. Virol. J. 3 (2006) 9
77. Schleiss M.R., and Lacayo J.C. The guinea pig model of congenital CMV infection. In: Reddehase M.J. (Ed). Cytomegaloviruses: Pathogenesis, Molecular Biology and Immunology (2006), Horizon Scientific Press Ltd., Wymondham, Norfolk, UK 525-550
78. Shanley J.D., and Pesanti E.L. The relation of viral replication to interstitial pneumonitis in murine cytomegalovirus lung infection. J. Infect. Dis. 151 (1985) 454-458
79. Smee D.F., Morris J.L., Leonhardt J.A., Mead J.R., Holy A., and Sidwell R.W. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob. Agents Chemother. 36 (1992) 1837-1842
80. Smee D.F., Sugiyama S.T., and Reist E.J. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice. Antimicrob. Agents Chemother. 38 (1994) 2165-2168
81. Stals F.S. Animal models for cytomegalovirus infections: rat CMV. In: Zak O., and Sande M.A. (Eds). Handbook of Animal Models of Infection (1999), Academic Press, San Diego 943-950
82. Stals F.S., Bosman F., van Boven C.P., and Bruggeman C.A. An animal model for therapeutic intervention studies of CMV infection in the immunocompromised host. Arch. Virol. 114 (1990) 91-107
83. Stals F.S., de Clercq E., and Bruggeman C.A. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. Antimicrob. Agents Chemother. 35 (1991) 2262-2266
84. Stals F.S., Zeytinoglu A., Havenith M., De Clercq E., and Bruggeman C.A. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. Antimicrob. Agents Chemother. 37 (1993) 218-223
85. Tural C., Romeu J., Sirera G., Andreu D., Conejero M., Ruiz S., Jou A., Bonjoch A., Ruiz L., Arno A., and Clotet B. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. 177 (1998) 1080-1083
86. Wang L.H., Peck R.W., Yin Y., Allanson J., Wiggs R., and Wire M.B. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47 (2003) 1334-1342
87. Weber O., Reefschlager J., Rubsamen-Waigmann H., Raddatz S., Hesseling M., and Habich D. A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models. Antiviral Chem. Chemother. 11 (2000) 51-59
88. Williams S.L., Hartline C.B., Kushner N.L., Harden E.A., Bidanset D.J., Drach J.C., Townsend L.B., Underwood M.R., Biron K.K., and Kern E.R. In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47 (2003) 2186-2192
89. Winston D.J., Ho W.G., Bartoni K., Du Mond C., Ebeling D.F., Buhles W.C., and Champlin R.E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. 118 (1993) 179-184
90. Winston D.J., Ho W.G., Bartoni K., Holland G.N., Mitsuyasu R.T., Gale R.P., Busuttil R.W., and Champlin R.E. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev. Infect. Dis. 10 Suppl. 3 (1988) S547-S553
91. Winston D.J., Yeager A.M., Chandrasekar P.H., Snydman D.R., Petersen F.B., and Territo M.C. Randomized controlled trial of oral ganciclovir and intravenous ganciclovir: prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin. Infect. Dis. 36 (2003) 749-758
92. Woolf N.K., Koehrn F.J., Harris J.P., and Richman D.D. Congenital cytomegalovirus labyrinthitis, and sensorineural hearing loss in guinea pigs. J. Infect. Dis. 160 (1989) 929-937
93. Woolf N.K., Ochi J.W., Silva E.J., Sharp P.A., Harris J.P., and Richman D.D. Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob. Agents Chemother. 32 (1988) 865-872
94. Yang Z.H., Lucia H.L., Tolman R.L., Colonno R.J., and Hsiung G.D. Effect of 2′-nor-cyclic GMP against guinea pig cytomegalovirus infection. Antimicrob. Agents Chemother. 33 (1989) 1563-1568